Date: 2012-09-04
Type of information: Collaboration agreement
Compound: EB66® cell line
Company: Vivalis (France) undisclosed major non-governmental vaccine research institute
Therapeutic area:
Type agreement:
Action mechanism:
Disease:
Details: Vivalis has signed an evaluation program with a major non-governmental vaccine research institute using Vivalis’s proprietary EB66® cell line. The program, performed at Vivalis, will assess the productivity of a new viral vector construct in EB66® cells used for the development of a new vaccine destined for a large, unmet need.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
